STOCK TITAN
  1. Home
  2. Sec-filings
  3. BPMC
  4. [25-NSE] Blueprint Medicines Corporation SEC Filing

[25-NSE] Blueprint Medicines Corporation SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
25-NSE
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock BPMC logo
Blueprint Medicines Corp

NASDAQ:BPMC

BPMC Rankings

#1701 Ranked by Market Cap
N/A Ranked by Dividends

BPMC Latest News

Jun 12, 2025
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
Jun 2, 2025
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
May 1, 2025
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Apr 25, 2025
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Mar 31, 2025
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

BPMC Latest SEC Filings

Jul 18, 2025
[S-8 POS] Blueprint Medicines Corporation SEC Filing
Jul 18, 2025
[S-8 POS] Blueprint Medicines Corporation SEC Filing
Jul 18, 2025
[S-8 POS] Blueprint Medicines Corporation SEC Filing
Jul 18, 2025
[S-8 POS] Blueprint Medicines Corporation SEC Filing
Jul 18, 2025
[S-8 POS] Blueprint Medicines Corporation SEC Filing

BPMC Stock Data

8.35B
63.82M
0.87%
106.87%
7.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE